Quarterly report pursuant to Section 13 or 15(d)

SEGMENTS

v3.21.2
SEGMENTS
 6 Months Ended
Jun. 30, 2021
SEGMENTS [Abstract]  
SEGMENTS
11.
SEGMENTS


The Company is engaged in the manufacture, marketing and development of specialty plasma-derived biologics.  The Company’s ADMA BioManufacturing segment reflects the Company’s immunoglobulin manufacturing, commercial and development operations in Boca Raton, FL, acquired on June 6, 2017 (see Note 1).  The Plasma Collection Centers segment as of June 30, 2021 consists of eight plasma collection facilities in various stages of approval and development located throughout the U.S., two of which hold an approved license with the FDA while a third facility has a BLA pending FDA approval. The Corporate segment includes general and administrative overhead expenses. The Company defines its segments as those business units whose operating results are regularly reviewed by the chief operating decision maker (“CODM”) to analyze performance and allocate resources. The Company’s CODM is its President and Chief Executive Officer.  Summarized financial information concerning reportable segments is shown in the following tables:

Three Months Ended June 30, 2021
  
   
ADMA
BioManufacturing
    
Plasma Collection
Centers
    
Corporate
    
Consolidated
  
                         
Revenues
  
$
16,347,880
    
$
1,447,001
    
$
35,709
    
$
17,830,590
  
                                 
Cost of product revenue
    
17,382,292
      
1,450,332
      
-
      
18,832,624
  
                                 
Loss from operations
    
(8,337,405
)
    
(2,794,219
)
    
(4,449,608
)
    
(15,581,232
)
                                 
Interest and other expense, net
    
(78,793
)
    
(366
)
    
(3,244,912
)
    
(3,324,071
)
                                 
Net loss
    
(8,416,198
)
    
(2,794,585
)
    
(7,694,520
)
    
(18,905,303
)
                                 
Depreciation and amortization expense
    
1,055,537
      
268,927
      
1,530
      
1,325,994
  
Total assets
    
169,799,509
      
20,593,411
      
42,420,872
      
232,813,792
  

Three Months Ended June 30, 2020
  
   
ADMA
BioManufacturing
    
Plasma Collection
Centers
    
Corporate
    
Consolidated
  
                         
Revenues
  
$
6,502,865
    
$
1,249,020
    
$
35,709
    
$
7,787,594
  
                                 
Cost of product revenue
    
12,237,141
      
1,258,488
      
-
      
13,495,629
  
                                 
Loss from operations
    
(12,852,835
)
    
(919,309
)
    
(3,351,681
)
    
(17,123,825
)
                                 
Interest and other expense, net
    
(235,442
)
    
(33
)
    
(2,818,791
)
    
(3,054,266
)
                                 
Net loss
    
(13,088,277
)
    
(919,342
)
    
(6,170,472
)
    
(20,178,091
)
                                 
Depreciation and amortization expense
    
772,241
      
111,106
      
2,305
      
885,652
  
Total assets
    
109,105,418
      
7,542,486
      
74,893,664
      
191,541,568
  

Six Months Ended June 30, 2021
  
   
ADMA
BioManufacturing
    
Plasma Collection
Centers
    
Corporate
    
Consolidated
  
                         
Revenues
  
$
29,768,923
    
$
4,038,868
    
$
71,417
    
$
33,879,208
  
                                 
Cost of product revenue
    
32,832,049
      
3,770,697
      
-
      
36,602,746
  
                                 
Loss from operations
    
(17,843,093
)
    
(4,765,060
)
    
(8,137,328
)
    
(30,745,481
)
                                 
Interest and other expense, net
    
(100,307
)
    
(750
)
    
(6,438,706
)
    
(6,539,763
)
                                 
Net loss
    
(17,943,400
)
    
(4,765,810
)
    
(14,576,034
)
    
(37,285,244
)
                                 
Capital expenditures
    
2,725,432
      
4,321,303
      
-
      
7,046,735
  
Depreciation and amortization expense
    
2,065,307
      
486,918
      
3,397
      
2,555,622
  

Six Months Ended June 30, 2020
  
   
ADMA
BioManufacturing
    
Plasma Collection
Centers
    
Corporate
    
Consolidated
  
                         
Revenues
  
$
14,246,139
    
$
3,669,782
    
$
71,417
    
$
17,987,338
  
                                 
Cost of product revenue
    
26,689,094
      
3,635,761
      
-
      
30,324,855
  
                                 
Loss from operations
    
(25,328,980
)
    
(1,376,464
)
    
(7,188,167
)
    
(33,893,611
)
                                 
Interest and other expense, net
    
(474,314
)
    
(33
)
    
(5,055,363
)
    
(5,529,710
)
                                 
Net loss
    
(25,803,294
)
    
(1,376,497
)
    
(12,243,530
)
    
(39,423,321
)
                                 
Capital expenditures
    
5,064,494
      
1,178,790
      
-
      
6,243,284
  
Depreciation and amortization expense
    
1,447,214
      
222,395
      
4,881
      
1,674,490
  

Net revenues according to geographic area, based on the location of where the product is shipped, is as follows:
   
Three Months Ended June 30,
    
Six Months Ended June 30,
  
   
2021
   
2020
   
2021
   
2020
 
United States
  
$
15,424,839
    
$
6,797,170
    
$
29,102,848
    
$
15,453,443
  
International
    
2,405,751
      
990,424
      
4,776,360
      
2,533,895
  
Total revenues
  
$
17,830,590
    
$
7,787,594
    
$
33,879,208
    
$
17,987,338